Last reviewed · How we verify
Cycloplegics
Cycloplegics is a Small molecule drug developed by Al-Azhar University. It is currently in Phase 1 development.
Cycloplegics are small molecule drugs used to induce paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation and the inability to focus on nearby objects. They are studied in various clinical trials for conditions such as dry eye, exotropia, diabetic retinopathy, and diabetic eye problems, and are used in conjunction with examinations like slit lamp examination and intraocular pressure measurement.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cycloplegics |
|---|---|
| Sponsor | Al-Azhar University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NCT00472524 (NA)
- Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma: a Prospective Single-center Cross-sectional Case-control Study (N/A)
- Assessing Patient Comfort, Anxiety, and Satisfaction During Cycloplegic Refraction: Comparing Conventional Drops With Rapid-Onset Cycloplegics (NA)
- Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis (Phase 3)
- A New More Efficient Cycloplegia Scheme (Phase 4)
- Understanding Retinal Vascular Changes During Pregnancy and the Impact on Maternal and Fetal Health (N/A)
- The Children's WEAR (Wearability and Evaluation of Adjustable Refraction) Trial(Phase 1&2) (NA)
- Development and Validation of a Deep Learning-based Myopia and Myopic Maculopathy Detection and Prediction System (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cycloplegics CI brief — competitive landscape report
- Cycloplegics updates RSS · CI watch RSS
- Al-Azhar University portfolio CI
Frequently asked questions about Cycloplegics
What is Cycloplegics?
Who makes Cycloplegics?
What development phase is Cycloplegics in?
Related
- Manufacturer: Al-Azhar University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing